Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Shares Outstanding (Diluted Average) (2016 - 2025)

Sonoma Pharmaceuticals has reported Shares Outstanding (Diluted Average) over the past 13 years, most recently at $1.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 13.87% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $1.7 million, up 13.87%, while the annual FY2025 figure was $1.2 million, 172.75% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $1.7 million at Sonoma Pharmaceuticals, up from $1.6 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $4.9 million in Q2 2023 and troughed at $2344.0 in Q3 2021.
  • A 5-year average of $1.3 million and a median of $1.0 million in 2024 define the central range for Shares Outstanding (Diluted Average).
  • Biggest five-year swings in Shares Outstanding (Diluted Average): tumbled 99.89% in 2021 and later surged 159074.46% in 2023.
  • Year by year, Shares Outstanding (Diluted Average) stood at $3080.0 in 2021, then skyrocketed by 100776.62% to $3.1 million in 2022, then tumbled by 88.7% to $351000.0 in 2023, then surged by 317.09% to $1.5 million in 2024, then rose by 13.87% to $1.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for SNOA at $1.7 million in Q4 2025, $1.6 million in Q3 2025, and $1.6 million in Q2 2025.